Concord Biotech Secures USFDA ANDA Approval for Tofacitinib Tablets 5 mg and 10 mg; Strengthens U.S. Generics Portfolio 10/06/2026 / Business Updates / Regulatory Approval / Product Approval Concord Biotech Secures USFDA ANDA Approval for Tofacitinib Tablets 5 mg and 10 mg; Strengthens U.S. Generics Portfolio Read Post »
Lupin Receives U.S. FDA Approval for Ranluspec (Ranibizumab), the First Interchangeable Biosimilar Referencing Lucentis in Multiple Formats 05/06/2026 / Regulatory Filings / Regulatory Approval / Product Approval Lupin Receives U.S. FDA Approval for Ranluspec (Ranibizumab), the First Interchangeable Biosimilar Referencing Lucentis in Multiple Formats Read Post »
